文献速递流行病学与生物统计医学教育与科研方法

不良事件虽被考虑但并非总被明确选为核心结局:一项更新系统评价

Adverse events are considered but not always explicitly selected as core outcomes in research: an updated systematic review.
PubMed 文献 · J Clin Epidemiol · 2025-06-25

该研究对2022年与2023年发表的58项和40项核心结局集(COS)开发研究进行更新系统评价,评估其与国际共识标准的依从性及不良事件结局的处理方式。所有研究均完全符合范围规范标准,但共识过程标准达标比例较低;约半数COS将不良事件域或明确命名的不良事件纳入核心结局。

要点

  • 2022年与2023年分别纳入58项和40项COS开发研究。
  • 范围规范标准全部完全符合,共识过程四项标准全部符合者分别占22%和33%。
  • 2022至2023年COS中约49%将不良事件域或明确命名的不良事件纳入核心结局。

核心结论

  • 对公认标准的依从性持续改善,包括患者参与,但共识过程标准的依从性仍需进一步提高。
  • COS开发者应明确说明并解释其考虑不良事件的方法及理由。

研究设计与样本

  • 采用既往系统评价方法,识别2022年与2023年发表或索引的COS开发研究。
  • 评估其对国际公认的COS开发共识标准的依从性,并使用现有结局分类法对核心结局进行分类。
  • 2022年更新纳入58项COS开发研究,2023年更新纳入40项研究。

主要发现

  • 范围规范标准在所有研究中均完全符合。
  • 利益相关方纳入标准在2022年研究中38项(66%)完全符合,在2023年研究中34项(85%)完全符合。
  • 共识过程全部四项标准均符合的比例较低,2022年为13项(22%),2023年为13项(33%)。
  • 2022至2023年COS中约一半(54项,49%)纳入不良事件域或明确命名不良事件为核心结局。

关键数值与推荐

  • 范围规范标准完全符合的研究:2022年与2023年均为全部研究。
  • 利益相关方纳入标准完全符合:2022年38项(66%),2023年34项(85%)。
  • 共识过程四项标准全部符合:2022年13项(22%),2023年13项(33%)。
  • 纳入不良事件域或明确命名不良事件为核心结局:2022至2023年COS中54项(49%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The annual systematic review update of published core outcome sets (COSs) by the Core Outcome Measures in Effectiveness Trials Initiative allows assessment of adherence to development standards. The objectives of this study were to assess the quality of COS development and the approach to the inclusion of adverse event outcomes. STUDY DESIGN AND SETTING: Studies reporting the development of a COS, published or indexed in 2022 and 2023, were identified using systematic review methods previously applied. Adherence to internationally agreed consensus-based standards for COS development was assessed. An existing outcome taxonomy was used to classify the core outcomes from all studies. The approach to consideration and inclusion of adverse event outcomes was examined. RESULTS: Fifty-eight COS development studies were included in the 2022 update and a further 40 studies in the 2023 update. Scope specification standards were fully met in all studies. Stakeholder inclusion standards were fully met in 38 (66%) and 34 (85%) of the 2022 and 2023 studies, respectively; the proportion meeting all four standards for the consensus process was lower, 13 (22%) and 13 (33%), respectively. The consideration of adverse events in the COS development process varied. Around half (54, 49%) of 2022-2023 COS included either the adverse events domain or specifically named adverse events as core outcomes. CONCLUSION: Continued improvement in adherence to recognized standards, including patient participation, is evident; however, further improvement is needed in relation to the consensus process standards. COS developers should be explicit about and explain the rationale for their approach to consideration of adverse events.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Gorst SL, Lucas JP, Dodd S, et al. Adverse events are considered but not always explicitly selected as core outcomes in research: an updated systematic review. J Clin Epidemiol. 2025. PMID: 40578404. doi:10.1016/j.jclinepi.2025.111889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。